Zlotkin S H, Fettes I M, Stallings V A
J Clin Endocrinol Metab. 1986 Nov;63(5):1229-32. doi: 10.1210/jcem-63-5-1229.
Children with the Prader-Willi syndrome have severe and often intractable hyperphagia unresponsive to medical or surgical treatment. Although the effect of opioid antagonists on suppressing appetite in humans has been inconsistent, we evaluated the effectiveness of a new opioid antagonist, naltrexone, in suppressing appetite in four obese adolescents with the Prader-Willi syndrome. Data were collected during the double blind oral administration of the drug and placebo for two 7-day periods. No clinical or biochemical toxicity was apparent during the naltrexone period, and measures of attention span, alertness, and mood did not change. Nutrient intake remained excessive during both the drug and placebo periods. Thus, naltrexone was ineffective in suppressing appetite, at least during the short term.
患有普拉德-威利综合征的儿童存在严重且常常难以治疗的食欲亢进，对药物或手术治疗均无反应。尽管阿片类拮抗剂对抑制人类食欲的效果并不一致，但我们评估了一种新型阿片类拮抗剂纳曲酮对四名患有普拉德-威利综合征的肥胖青少年抑制食欲的有效性。在两个为期7天的时间段内，对药物和安慰剂进行双盲口服给药期间收集数据。在纳曲酮给药期间未出现明显的临床或生化毒性，注意力持续时间、警觉性和情绪指标也未发生变化。在药物和安慰剂给药期间，营养摄入均仍然过多。因此，至少在短期内，纳曲酮抑制食欲无效。
